A
Anil Potti
Researcher at Duke University
Publications - 93
Citations - 7777
Anil Potti is an academic researcher from Duke University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 36, co-authored 93 publications receiving 7451 citations.
Papers
More filters
Journal ArticleDOI
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Andrea Bild,Guang Yao,Jeffrey T. Chang,Quanli Wang,Anil Potti,Dawn Chasse,Mary Beth Joshi,David H. Harpole,Johnathan M. Lancaster,Andrew Berchuck,John A. Olson,Jeffrey R. Marks,Holly K. Dressman,Mike West,Joseph R. Nevins +14 more
TL;DR: It is shown that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways and linked with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogens pathway signatures to guide the use of targeted therapeutics.
Journal ArticleDOI
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
Carey K. Anders,David S. Hsu,Gloria Broadwater,Chaitanya R. Acharya,John A. Foekens,Yi Zhang,Yixin Wang,P. Kelly Marcom,Jeffrey R. Marks,Phillip G. Febbo,Joseph R. Nevins,Anil Potti,Kimberly L. Blackwell +12 more
TL;DR: This large-scale genomic analysis illustrates that breast cancer arising in young women is a unique biologic entity driven by unifying oncogenic signaling pathways, is characterized by less hormone sensitivity and higher HER-2/EGFR expression, and warrants further study to offer this poor-prognosis group of women better preventative and therapeutic options.
Journal ArticleDOI
A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.
Anil Potti,Sayan Mukherjee,Rebecca P. Petersen,Holly K. Dressman,Andrea Bild,Jason I. Koontz,Robert A. Kratzke,Mark A. Watson,Michael J. Kelley,Geoffrey S. Ginsburg,Mike West,David H. Harpole,Joseph R. Nevins +12 more
TL;DR: The lung metagene model provides a potential mechanism to refine the estimation of a patient's risk of disease recurrence and, in principle, to alter decisions regarding the use of adjuvant chemotherapy in early-stage NSCLC.
Journal ArticleDOI
Genomic signatures to guide the use of chemotherapeutics.
Anil Potti,Holly K. Dressman,Andrea H. Bild,Richard F. Riedel,Gina Chan,Robyn Sayer,Janiel M. Cragun,Hope Cottrill,Michael J. Kelley,Rebecca P. Petersen,David H. Harpole,Jeffrey R. Marks,Andrew Berchuck,Geoffrey S. Ginsburg,Phillip G. Febbo,Johnathan M. Lancaster,Joseph R. Nevins +16 more
TL;DR: Using in vitro drug sensitivity data coupled with Affymetrix microarray data, gene expression signatures that predict sensitivity to individual chemotherapeutic drugs are developed that can accurately predict clinical response in individuals treated with these drugs.
Journal ArticleDOI
A pathway-based classification of human breast cancer
Michael L. Gatza,Joseph E. Lucas,William T. Barry,Jong Wook Kim,Quanli Wang,Matthew D. Crawford,Michael B. Datto,Michael J. Kelley,Bernard Mathey-Prevot,Anil Potti,Joseph R. Nevins +10 more
TL;DR: A classification scheme for human breast cancer making use of patterns of pathway activity to build on previous subtype characterizations using intrinsic gene expression signatures, to provide a functional interpretation of the gene expression data that can be linked to therapeutic options.